Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
Martínez-Cuadrón D, Gil C, Serrano J, Rodríguez G, Pérez-Oteyza J, García-Boyero R, Jiménez-Bravo S, Vives S, Vidriales MB, Lavilla E, Pérez-Simón JA, Tormo M, Colorado M, Bergua J, López JA, Herrera P, Hernández-Campo P, Gorrochategui J, Primo D, Rojas JL, Villoria J, Moscardó F, Troconiz I, Linares Gómez M, Martínez-López J, Ballesteros J, Sanz M, Montesinos P; Spanish PETHEMA group. Martínez-Cuadrón D, et al. Among authors: moscardo f. Leuk Res. 2019 Jan;76:1-10. doi: 10.1016/j.leukres.2018.11.006. Epub 2018 Nov 13. Leuk Res. 2019. PMID: 30468991 Free article.
Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine.
Bennett TA, Montesinos P, Moscardo F, Martinez-Cuadron D, Martinez J, Sierra J, García R, de Oteyza JP, Fernandez P, Serrano J, Fernandez A, Herrera P, Gonzalez A, Bethancourt C, Rodriguez-Macias G, Alonso A, Vera JA, Navas B, Lavilla E, Lopez JA, Jimenez S, Simiele A, Vidriales B, Gonzalez BJ, Burgaleta C, Hernandez Rivas JA, Mascuñano RC, Bautista G, Perez Simon JA, Fuente Ade L, Rayón C, Troconiz IF, Janda A, Bosanquet AG, Hernandez-Campo P, Primo D, Lopez R, Liebana B, Rojas JL, Gorrochategui J, Sanz MA, Ballesteros J. Bennett TA, et al. Among authors: moscardo f. Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):305-18. doi: 10.1016/j.clml.2013.11.006. Epub 2013 Nov 15. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24468131 Free article.
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups. Martínez-Cuadrón D, et al. Among authors: moscardo f. Ann Hematol. 2018 May;97(5):763-772. doi: 10.1007/s00277-018-3229-5. Epub 2018 Feb 2. Ann Hematol. 2018. PMID: 29392425 Clinical Trial.
Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.
Martínez-Cuadrón D, Montesinos P, Oriol A, Salamero O, Vidriales B, Bergua J, Herrera P, Vives S, Sanz J, Carpio C, Rodríguez-Veiga R, Moscardó F, Sanz MA. Martínez-Cuadrón D, et al. Among authors: moscardo f. Ann Hematol. 2014 Jan;93(1):43-6. doi: 10.1007/s00277-013-1914-y. Epub 2013 Oct 1. Ann Hematol. 2014. PMID: 24081577 Clinical Trial.
Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients.
Fuster O, Llop M, Dolz S, García P, Such E, Ibáñez M, Luna I, Gómez I, López M, Cervera J, Montesinos P, Moscardó F, Cordón L, Solves P, de Juan I, Palanca S, Bolufer P, Sanz MÁ, Barragán E. Fuster O, et al. Among authors: moscardo f. Leuk Res. 2013 Dec;37(12):1690-6. doi: 10.1016/j.leukres.2013.09.015. Epub 2013 Sep 21. Leuk Res. 2013. PMID: 24199710
WT1 isoform expression pattern in acute myeloid leukemia.
Luna I, Such E, Cervera J, Barragán E, Ibañez M, Gómez-Seguí I, López-Pavía M, Llop M, Fuster O, Dolz S, Oltra S, Alonso C, Vera B, Lorenzo I, Martínez-Cuadrón D, Montesinos P, Senent ML, Moscardó F, Bolufer P, Sanz MA. Luna I, et al. Among authors: moscardo f. Leuk Res. 2013 Dec;37(12):1744-9. doi: 10.1016/j.leukres.2013.10.009. Epub 2013 Oct 22. Leuk Res. 2013. PMID: 24211094
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE, Montesinos P, Herrero MJ, Moscardó F, Bosó V, Rojas L, Martínez-Cuadrón D, Hervás D, Boluda B, García-Robles A, Rodríguez-Veiga R, Martín-Cerezuela M, Cervera J, Sendra L, Sanz J, Miguel A, Lorenzo I, Poveda JL, Sanz MÁ, Aliño SF. Megías-Vericat JE, et al. Among authors: moscardo f. Leuk Lymphoma. 2017 May;58(5):1197-1206. doi: 10.1080/10428194.2016.1231405. Epub 2016 Oct 4. Leuk Lymphoma. 2017. PMID: 27701910
Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
Megías-Vericat JE, Montesinos P, Herrero MJ, Moscardó F, Bosó V, Martínez-Cuadrón D, Rojas L, Rodríguez-Veiga R, Boluda B, Sendra L, Cervera J, Poveda JL, Sanz MÁ, Aliño SF. Megías-Vericat JE, et al. Among authors: moscardo f. Leuk Lymphoma. 2017 Dec;58(12):2880-2894. doi: 10.1080/10428194.2017.1323267. Epub 2017 Jun 2. Leuk Lymphoma. 2017. PMID: 28573946
73 results